JP-2022530667-A5 -

Dates

Publication Date

20230512

Application Date

20200429

Description

An antibody is provided herein that competes with the antibody or antigen-binding fragment described in any one of claims 1247 to 1250 for binding to RP2, wherein the antibody binds to human RP2 or mouse RP2. In certain embodiments, for example, the following are provided: (Item 1) An antibody or its antigen-binding fragment comprising at least one of variable heavy chain complementarity determining regions 1 (CDR-H1), CDR-H2, and CDR-H3, (a) The CDR-H1 comprises a reconstructed polypeptide consensus sequence selected from any one of sequence numbers 543 to 813, (a) The CDR-H2 comprises a reconstructed polypeptide consensus sequence selected from any one of sequence numbers 1085 to 1355, (c) An antibody or an antigen-binding fragment thereof, wherein the CDR-H3 comprises a reconstituted polypeptide consensus sequence selected from any one of sequence numbers 1627 to 1897. (Item 2) An antibody or its antigen-binding fragment comprising at least one of variable light chain complementarity determining regions 1 (CDR-L1), CDR-L2, and CDR-L3, (a) The CDR-L1 comprises a reconstructed polypeptide consensus sequence selected from any one of sequence numbers 814 to 1084, (b) The CDR-L2 comprises a reconstructed polypeptide consensus sequence selected from any one of sequence numbers 1356 to 1626, (c) An antibody or an antigen-binding fragment thereof, wherein CDR-L3 comprises a reconstituted polypeptide consensus sequence selected from any one of sequence numbers 1898 to 2168. (Item 3) (a) Variable heavy chain complementarity determination regions 1 (CDR-H1), CDR-H2, and CDR-H3, (i) The CDR-H1 comprises a reconstructed polypeptide consensus sequence selected from any one of sequence numbers 543 to 813, (ii) The CDR-H2 comprises a reconstructed polypeptide consensus sequence selected from any one of sequence numbers 1085 to 1355, (iii) The variable heavy chain complementarity determination region 1 (CDR-H1), CDR-H2, and CDR-H3 include a reconstructed polypeptide consensus sequence selected from any one of sequence numbers 1627 to 1897, (b) Variable light chain complementarity determination regions 1 (CDR-L1), CDR-L2, and CDR-L3, (i) The CDR-L1 comprises a reconstructed polypeptide consensus sequence selected from any one of sequence numbers 814 to 1084, (ii) The CDR-L2 comprises a reconstructed polypeptide consensus sequence selected from any one of sequence numbers 1356 to 1626, (iii) An antibody or antigen-binding fragment comprising a variable light chain complementarity determination region 1 (CDR-L1), CDR-L2, and CDR-L3, wherein CDR-L3 contains a reconstituted polypeptide consensus sequence selected from any one of sequence numbers 1898 to 2168. (Item 4) The antibody or its antigen-binding fragment according to any one of items 1 to 3, wherein the antibody comprises an IgG, IgA, or IgM antibody. (Item 5) The antibody or antigen-binding fragment according to item 4, wherein the IgG comprises IgG1, IgG2, IgG3, IgG4, IgG1, or IgG2. (Item 6) The antibody or its antigen-binding fragment according to any one of items 1 to 5, wherein the antibody includes a chimeric antibody, a humanized antibody, a human antibody, a monoclonal antibody, a deimmunized antibody, a bispecific antibody, a multispecific antibody, a polyvalent antibody, or a combination thereof. (Item 7) The antibody or antigen-binding fragment according to any one of items 1 to 6, wherein the antigen-binding fragment comprises Fab, Fab', Fab'-SH, Fv, scFv, F(ab')2, diabody, linear antibody, single-domain antibody (sdAb), camel V HH domain, or a multispecific antibody formed from an antibody fragment. (Item 8) The antibody or antigen-binding fragment according to any one of items 1 to 7, wherein the antibody or antigen-binding fragment is recombinant or synthetic. (Item 9) The antibody or antigen-binding fragment according to any one of items 1 to 8, further comprising an enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, drug, toxin, or a combination thereof. (Item 10) The antibody or antigen-binding fragment according to any one of items 1 to 9, wherein the antibody or antigen-binding fragment is cytolytic against tumor cells or cancer cells. (Item 11) The antibody or antigen-binding fragment thereof, according to any one of items 1 to 10, wherein the antibody or antigen-binding fragment thereof inhibits tumor growth or cancer cell growth. (Item 12) An antibody or antigen-binding fragment according to item 10 or item 11, which is useful for the treatment of bladder cancer, wherein the bladder cancer is urothelial carcinoma of the bladder, squamous cell carcinoma of the bladder, adenocarcinoma of the bladder, or small cell carcinoma of the bladder. (Item 13) An antibody or antigen-binding fragment according to item 10 or item 11, which is useful for treating brain tumors, wherein the brain tumor is a glioma, meningioma, pituitary adenoma, vestibular schwannoma, nerve sheath tumor, undifferentiated neur